InsidersTradesSigma
Laurus Labs Limited Stock: price and directors' dealings · India · SEBI (PIT + SAST)
Track the Laurus Labs Limited stock price and the full insider trade history of the company, a listed equity based in India. Shares trade on IN IN, under the supervision of SEBI (PIT + SAST). Operating in the Health Care sector, Laurus Labs Limited has recorded 94 reports. Market capitalisation: €331bn. The latest transaction was disclosed on 6 December 2024 (Pledge). Among the most active insiders: NURUBHASHA BABCHAND. The full history is accessible without an account.
94
Insider Decl.
0
Thresholds
€230,889
9 ops.
Buy Volume
€11m
63 ops.
Sell Volume
11Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 13,292 of 26,211 companies
51.5
score / 100
Value29
Quality75
FCF yld0.7%
Earn yld1.1%
EV/EBITDA44.7x
ROE18%
Gross mgn59%
Net mgn13%
Debt/EBITDA1.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 6 December 2024
Declarations94 total
200,000 shares@ ₹576.4053.2% of flowEquity SharesSEBI:f056e113b6d76c2ca2150ffbc16b0d83f54e802b
10,000 shares@ ₹376.00100.0% of flowEquity SharesSEBI:65a5ebe59fea5b64a320934230be0c60f5938025
3,992 shares@ ₹578.699951.9% of flowEquity SharesSEBI:533ed4ab7f20b74154ba14b1ace39f1f40980e44
Ideal exit: 11 Dec 2022 (T+270)
2,906 shares@ ₹578.699937.9% of flowEquity SharesSEBI:f42d38f3df2b5437d430c3531e677c3a8b4b41c6
Ideal exit: 9 Dec 2022 (T+270)
788 shares@ ₹578.700510.2% of flowEquity SharesSEBI:3366fdec688fd4954445e2ed651c1ee188c066c3
Ideal exit: 12 Dec 2022 (T+270)
2,275 shares@ ₹525.9451100.0% of flowEquity SharesSEBI:9918aa918bf48f376276e65749d72798b1cc2fd3
10,000 shares@ ₹539.6671100.0% of flowEquity SharesSEBI:38648633ccebbcc5b348287b244fdaf2237aa5f6
Ideal exit: 12 Nov 2022 (T+270)
10,245 shares@ ₹505.00100.0% of flowEquity SharesSEBI:3c64216c2911c4481747e64cfffb129684c055bf
12,000 shares@ ₹657.9167100.0% of flowEquity SharesSEBI:89cce66f57a00d5b944c713995d2af8d7b6e43a9
1,000 shares@ ₹650.007.8% of flowEquity SharesSEBI:70dd415dbf1f2fff1e417e60f5b64c1724e22ace
4,000 shares@ ₹650.9031.8% of flowEquity SharesSEBI:38a73e3679e9a0368c34fa465ac3b651400cd155
5,500 shares@ ₹657.000.0000% mcap100.0% of flowEquity SharesSEBI:3b480afbc23a058629b405c641fa3064b07d5c5c
3,000 shares@ ₹669.76430.0000% mcap100.0% of flowEquity SharesSEBI:69648c1b026d439e29642d979c59be7d7a2381e4
18,120 shares@ ₹703.27230.0000% mcap4.9% of flowEquity SharesSEBI:47edc5b96d5919ef4a2dcb5a7d387403d19e4e4c
20,000 shares@ ₹700.000.0000% mcap5.3% of flowEquity SharesSEBI:b764e1f7fab1b1c9f44ecd5b7252fd53243b16b9
67,657 shares@ ₹702.89240.0002% mcap18.2% of flowEquity SharesSEBI:8679313bcf167fe661ae23babba4951a458450ed
1,445 shares@ ₹700.99930.0000% mcap50.1% of flowEquity SharesSEBI:ff4d7d5e25c0c2d0470fdb1a36453dbb2b20936d
2,910 shares@ ₹688.65020.0000% mcap36.5% of flowEquity SharesSEBI:d7094110df1c126fb2f2988a96abed8cbf40527c
Ideal exit: 27 Mar 2022 (T+270)
5,060 shares@ ₹688.650.0000% mcap63.5% of flowEquity SharesSEBI:d841479378fac38ef620176828126f861f5e726f
20,000 shares@ ₹686.000.0000% mcap50.0% of flowEquity SharesSEBI:db9fb14bf57d4a899c78847d77441a2534d75dca
6,500 shares@ ₹688.75150.0000% mcap89.0% of flowEquity SharesSEBI:bca8cc04a27c9c9810a2152f45418010ba142aa3
15,000 shares@ ₹687.33330.0000% mcap100.0% of flowEquity SharesSEBI:c1c3cddf953e72821edf1b79140eee6568300dff
100,000 shares@ ₹683.000.0002% mcap68.8% of flowEquity SharesSEBI:cca0346f49eb11a88e6d509fba87315a476c63c6
1,500 shares@ ₹466.170.0000% mcap11.0% of flowEquity SharesSEBI:3416b6b38ae404ebeaeeebb5147776a5a23dd514
25 of 94 declarations
About Laurus Labs Limited
Laurus Labs Limited is an Indian pharmaceutical company engaged in the research, development, and manufacturing of generic pharmaceutical products. It primarily focuses on antiretroviral drugs and healthcare products.